Risk factors for rapid axial length elongation with low concentration atropine for myopia control
Abstract Three hundred and twenty-eight myopic children, randomized to use either 0.01% (N = 166) or 0.02% (N = 162) atropine were enrolled in this study. Gender, age, body mass index(BMI), parental myopia status, atropine concentration used, pupil diameter, amplitude of accommodation, spherical equ...
Guardado en:
Autores principales: | Aicun Fu, Fiona Stapleton, Li Wei, Weiqun Wang, Bingxin Zhao, Kathleen Watt, Shiao Yu, Can Cui, Yong Lyu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fbf547cf5e2341789b359f2851742fac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
por: Can Cui, et al.
Publicado: (2021) -
Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
por: Loreto V T Rose, et al.
Publicado: (2021) -
Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia
por: Pugazhendhi S, et al.
Publicado: (2020) -
Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia
por: Po-Hsiang Kao, et al.
Publicado: (2021) -
The Effect of Axial Length Elongation on Corneal Biomechanical Property
por: Guihua Liu, et al.
Publicado: (2021)